Asparaginase is an important component for treatment of childhood acute lymphoblastic leukemia (ALL). The basis for interindividual differences in asparaginase sensitivity remains unclear. To comprehensively identify genetic variants important in the cytotoxicity of asparaginase, we used a genomewide association approach using the HapMap lymphoblastoid cell lines (87 CEU trio members) and 54 primary ALL leukemic blast samples at diagnosis. Asparaginase sensitivity was assessed as the drug concentration necessary to inhibit 50% of growth (inhibitory concentration (IC) 50 ). In CEU lines, we tested 2 390 203 single-nucleotide polymorphism (SNP) genotypes at the individual SNP (Po0.001) and gene level (Po0.05), and identified 329 SNPs representing 94 genes that were associated with asparaginase IC 50 . The aspartate metabolism pathway was the most overrepresented among 199 pathways evaluated (P ¼ 8.1 Â 10 À3 ), with primary involvement of adenylosuccinate lyase and aspartyl-tRNA synthetase genes. We validated that SNPs in the aspartate metabolism pathway were also associated with asparaginase sensitivity in primary ALL leukemic blast samples (P ¼ 5.5 Â 10 À5 ). Our genome-wide interrogation of CEU cell lines and primary ALL blasts revealed that inherited genomic interindividual variation in a plausible candidate pathway can contribute to asparaginase sensitivity.
Introduction
Asparaginase is an effective agent in treating childhood acute lymphoblastic leukemia (ALL). There is substantial interpatient variability in the inherent sensitivity of ALL to asparaginase. [1] [2] [3] [4] Both the ex vivo sensitivity of primary ALL blasts to asparaginase and the early in vivo response to a single dose of asparaginase have been linked to prognosis in childhood ALL. [5] [6] [7] [8] [9] Asparaginase exerts its antileukemic activity by converting asparagine to aspartic acid in extracellular fluid. 10 Most normal cells can synthesize asparagine, but leukemic lymphoblasts are sensitive to the depletion of extracellular asparagine, putatively because they express low levels of asparagine synthetase (ASNS) [11] [12] [13] or they lack the ability to upregulate the expression of ASNS when exposed to asparaginase. 14, 15 The relative inability of leukemic lymphoblasts to produce their own asparagine to compensate for the shortage of extracellular asparagine reduces asparagine-dependent protein synthesis, resulting in leukemic cell death. 16 However, some recent studies have reported conflicting data on the relationship between the levels of ASNS and resistance to asparaginase. [17] [18] [19] [20] [21] [22] [23] [24] Resistance to asparaginase can also be caused by the development of antibodies against asparaginase, 25 by altered expression of genes involved in apoptosis 26 and protein synthesis 24 and by secretion of asparagine by bone marrow mesenchymal cells. 19 However, the basis for interindividual differences in asparaginase sensitivity remains unclear, and a genome-wide approach has not yet been used to interrogate the effect of inherited genomic variation on asparaginase sensitivity.
In this study, we used a genome-wide approach to investigate genomic determinants of asparaginase sensitivity in lymphoblastoid HapMap cell lines and in leukemic cells from patients with ALL.
Materials and methods

Cell lines
Epstein-Barr virus-transformed B-lymphoblastoid cell lines derived from 30 Center d'Etude du Polymorphism Humain family trios (CEU) and from 30 trios collected from Yoruba in Ibadan, Nigeria (YRI), were obtained from the Coriell Institute of Medicine (Camden, NJ, USA; http://www.ccr.coriell.org). Cell lines were maintained in log phase in RPMI-1640 medium (BioWhittaker, Walkersfield, MD, USA) with 15% fetal bovine serum (Hyclone, Logan, UT, USA) and 20 mM L-glutamine (Invitrogen, Carlsbad, CA, USA) and maintained in culture in a humidified 5% CO 2 incubator at 37 1C.
Samples from patients with ALL
Primary bone marrow samples were obtained from 54 children with newly diagnosed ALL who were treated on protocol Total XV 27 after obtaining informed consent from them or from their parents/guardians, with assent from the patients, as appropriate. All patients were treated at St Jude Children's Research Hospital. This study and use of these samples were approved by the institutional review board at St Jude.
GeneChip Human Exon 1.0 ST Array were downloaded from the website (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc ¼ GSE7761). High-quality germline DNA was extracted using a blood and cell culture DNA kit (Qiagen, Valencia, CA, USA) from normal blood leukocytes of patients after they achieved complete remission. Patient samples were genotyped using the Affymetrix GeneChip Human Mapping 500 K set (Affymetrix, Santa Clara, CA, USA), as described previously. 28 SNPs with minor allele frequencies less than 1% were excluded from all analyses.
To verify genotypes of interest, we genotyped 5 adenylosuccinate lyase (ADSL) and aspartyl-tRNA synthetase (DARS) SNPs in 19 CEU cell lines that cover all three variant genotypes, using ABI SNPlex technology. We observed 99% concordance between genotype data downloaded from HapMap and the experimentally determined genotypes. In addition, we have genotyped 168 SNPs using the Sequenom iPLEX technology (as implemented by Dr Soma Das, Department of Human Genetics, University of Chicago) in over 400 patients with ALL that had been typed using the Affymetrix GeneChip Human Mapping 500 K set arrays; we observed an average genotyping concordance of greater than 99% between the two genotyping methods. This indicates that the genotype data obtained from the Affymetrix SNP arrays were of high accuracy.
In vitro sensitivity (MTT) assay
In vitro drug sensitivity was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide (MTT) assay described previously with slight modifications. 24, 29, 30 For CEU cell lines, cells were plated at a density of 2.5 Â 10 5 cells/ml on day 0 and incubated for 24 h. Cells were then exposed to asparaginase (Elspar, Merck & Co. Inc., West Point, PA, USA) (treated) at six different concentrations (0.003, 0.024, 0.195, 1.56, 12.5 and 100 IU/ml) or to culture media (untreated) in a 96-well plate format. After a 48-h incubation, 5 mg/ml of MTT (Sigma, St Louis, MO, USA) was added, and cells were incubated for an additional 4 h at 37 1C. Acidified (0.04 N HCl) isopropanol was added to dissolve formazan crystals produced by viable cells, and the resultant solution was subjected to absorbance measurement at 570 nm (and 720 nm for subtracting background signals). Viability at each tested concentration was computed as a percentage of the viability measured in paired untreated cells, thereby accounting for inherent differences in viability among cell lines and primary cells. The inhibitory concentration (IC) 50 value (drug concentration lethal for 50% of treated cells) was estimated from nonlinear curve fitting by the ADAPT5 Beta program for concentration vs viability (Supplementary Figure S1 ). 31 The MTT assay was performed at least twice at different passages and final IC 50 values represented the median of 2-8 separate experiments per cell line. For ALL patient samples, cells were plated at 2 Â 10 6 cells/ml on day 0 and exposed to six serial dilutions of asparaginase (0.003, 0.016, 0.08, 0.4, 2 and 10 IU/ml) on the same day. After a 96-h incubation, MTT was added and cell viability was measured 6 h later using the procedure described above. It has been demonstrated previously that 96 h of drug incubation is necessary to achieve cytotoxic effect in primary ALL cells, and a plateau is reached for optical density measurement after 4-8 h of MTT incubation with primary ALL cells. 32 A cytospin slide for untreated cells was prepared on days 0 and 4. The percentage of leukemic blasts in each sample was determined by Geimsa stain. Those with 90% or more leukemic cells on day 0, with 70% or more leukemic cells in the untreated wells after 4 days of culture, and with an optical density greater than 0.05 arbitrary units were considered suitable for evaluation. For samples in which 50% cytotoxicity was not achieved even at the highest tested concentration (that is, complete resistance), the IC 50 value was assigned as twice the highest concentration tested. 33 For cells with viabilities less than 50% at all tested concentrations (that is, high sensitivity), the IC 50 Pathway analysis. We ranked genes on the basis of the associations of their SNPs with asparaginase IC 50 . We then queried the KEGG database to determine those pathways that comprised genes that were overrepresented with respect to their association with asparaginase sensitivity. Specifically, for each of the 199 KEGG pathways with genes containing interrogated SNPs, we calculated the proportion of genes in that pathway with SNPs associated with asparaginase IC 50 and compared it with the proportion of genes with SNPs associated with IC 50 among all interrogated genes that were not in that pathway; we tested for differences in proportions using Fisher's exact test.
Multivariate model to assess association of asparaginase IC 50 with variation in genes in the highest ranked pathway. After identifying the pathway for which genomic variation relating to asparaginase sensitivity was most overrepresented, we applied a random forests model by using all typed SNPs in the given pathway to compute a predicted IC 50 value for each CEU cell line. 34 Pathway analyses are subject to the criticism that there is inherent bias in estimating regression error; random forests is an ensemble tree-based regression algorithm for performing regressions in pathway-based analysis that allows for an unbiased estimate of the regression error (details in Supplementary Material). Pearson's correlation was used to estimate the correlation between the predicted IC 50 and observed IC 50 values.
Association analyses of asparaginase IC 50 with other phenotypes. The association between IC 50 and gene expression in CEU lines was evaluated on the basis of a linear mixedeffects model by adjusting for relatedness within the trios.
The structure of relatedness within a trio was modeled using a Toeplitz structure with two diagonal bands. 35 We determined the extent of correlation between the asparaginase IC 50 values that we determined experimentally and the IC 50 values to daunorubicin, cisplatin and etoposide that we downloaded from the PharmGKB website (http://www.pharmgkb.org/) using Spearman's correlation analysis. We compared the intratrio (child to parents) variability in asparaginase IC 50 with that expected in unrelated trios (see Supplementary Material for details).
Results
Genome-wide association analyses for CEU cell lines
Of 88 cell lines tested, one displayed erratic growth characteristics and we were unable to accurately estimate its IC 50 value. For the remaining 87 CEU cell lines with available IC 50 values, the median IC 50 value was 0.39 IU/ml (range 0.16-4.52 IU/ml) ( Figure 1 ). There was a 28-fold interindividual variation in IC 50 values. Of the 2 390 203 SNP genotypes tested for their association with asparaginase IC 50 in 87 CEU cell lines, the top-ranked SNP was rs12609807 (P ¼ 4.9 Â 10 À6 ). There were 84 859 SNP genotypes associated with asparaginase IC 50 at the Po0.05 level (Supplementary Figure S2) . At the gene level, SNPs representing 939 genes were identified at Po0.05. The overlap of all the evaluable SNP genotypes (at a P-value threshold of Po1.0 Â 10
À3
) and genes (at Po0.05) yielded 329 SNPs representing 94 genes (Figure 2a ).
Pathway analysis in CEU cell lines
We conducted a pathway analysis of these top-ranked 94 genes by querying the KEGG database (Figure 2a Table S1 ). (b) The most overrepresented pathway based on the genome-wide analysis of CEU lines was the aspartate metabolism pathway (retrieval from KEGG hsa00252). Genes in green, pink and yellow indicate those hosting SNPs at the Po0.05 level in CEU lines, ALL patient samples and both groups, respectively. could be annotated to 27 pathways (Supplementary Table S1 ). The top-ranked KEGG pathway that was overrepresented by the 94 genes (P ¼ 0.009) was the alanine/aspartate metabolism pathway. There were two highly ranked genes in this pathway: ADSL and DARS. The genotypes of two SNPs (rs8135371 and rs17001863) annotated to ADSL and of five SNPs (rs3768998, rs2278683, rs11893318, rs2322725 and rs7587285) annotated to DARS were significantly associated with asparaginase IC 50 at the Po0.001 level (Table 1) . Interestingly, these two genes, ADSL and DARS, were directly involved in aspartate metabolism rather than in alanine metabolism (Figure 2b ).
The multivariate model to predict asparaginase IC 50 in CEU cell lines based on genotypes in the highest ranked pathway
Among genes identified in the alanine/aspartate metabolism pathway, 19 genes were directly involved in aspartate metabolism, and we therefore focused on SNPs annotated to these 19 genes (Figure 2b) ; the remainder were involved in alanine metabolism. To examine the overall contributions of SNPs in the aspartate metabolism pathway to asparaginase IC 50 , we applied a random forests model to compute a predicted IC 50 value for each CEU cell line (Figure 3) . The genotypes of 1600 SNPs represented in the aspartate metabolism pathway were available Figure 3 Approach using the random forests model analysis in CEU cell lines and in ALL patient samples. SNPs representing the aspartate metabolism pathway from the exon array or Affymetrix SNP array were selected. After applying filter criteria, the random forests model was applied on the remaining SNPs to predict asparaginase IC 50 in each sample. Figure 4) . Interestingly, none of the SNPs annotated to ASNS showed a strong association with asparaginase IC 50 . For comparison, we created 500 randomly composed gene sets, with 19 genes in each set, and applied the random forests model for each gene set. None of the 500 gene sets had a P-value less than 1.1 Â 10
À3
, the P-value observed for the SNPs constituting the aspartate metabolism pathway (Supplementary Table S3 ). This demonstrated that the association between SNPs in the aspartate metabolism pathway and asparaginase IC 50 was unlikely to have been observed by chance, because no other similarly constructed random forests gave as good a prediction.
Of the top seven SNPs in the top-ranked pathway of aspartate metabolism in CEU cell lines, one (rs3768998 in DARS, P ¼ 5.82 Â 10 À4 in CEU) was also associated with asparaginase IC 50 in YRI cell lines (P ¼ 0.04 in YRI) (Supplementary Table S5 ). The G allele at this genotype was associated with higher IC 50 in both CEU and YRI cell lines.
Relationship between sensitivity to asparaginase and to other drugs in CEU cell lines
Spearman's rho estimates for the association between asparaginase IC 50 and that of other antileukemic drugs were 0.21 (P ¼ 0.052) for daunorubicin, 0.41 (P ¼ 0.00017) for cisplatin and 0.32 (P ¼ 0.0036) for etoposide. A small percentage of SNPs associated with IC 50 to asparaginase were overlapping with sensitivity to the other three drugs (Supplementary Table S4) , and no SNPs were significantly associated with sensitivity to all four drugs at Po0.001 level.
The association between the top seven SNPs and gene expression
We tested the association between genotypes for the top seven SNPs in the aspartate metabolism pathway and gene expression levels in CEU cell lines ( Table 1 ). The genotypes of rs8135371 and rs17001863 in ADSL significantly correlated with ADSL gene expression. The numbers of copies of the C allele of rs8135371 and the G allele of rs17001863 were associated with increased expression of ADSL and also with higher IC 50 (Supplementary Figure S3) . In a concordant manner, cells with higher ADSL expression tended to have higher IC 50 (Supplementary Figure S3) .
Testing the aspartate metabolism pathway in clinical ALL blast samples
The median IC 50 value in 54 primary leukemic samples was 0.15 IU/ml (range 1.0 Â 10 À4 -20.0 IU/ml) ( Figure 1 ). We did not observe significant differences (P ¼ 0.58, the Kruskal-Wallis test) in IC 50 values by ALL subtype (Supplementary Figure S4) , although the number of samples in each subgroup was small (Figure 1) .
We did not find that the germline SNPs that were most associated with IC50 in CEU cell lines were associated with IC 50 in primary leukemic samples (Table 1) . To assess whether the same pathway important for asparaginase sensitivity in CEU cell lines is also important in primary patient samples, we applied the random forests model to the 148 evaluable SNPs representing the 19 genes involved in aspartate metabolism that were evaluable and interrogated on the Affy 500 K SNP chip (Figure 3) . The predicted IC 50 values were significantly correlated with the observed IC 50 values (P ¼ 5.5 Â 10
À5
) in this set of 54 primary patient samples, indicating that the variation in the aspartate metabolic pathway was also important for primary ALL. Of the 148 SNPs in the aspartate pathway, 11 were associated with IC 50 at the Po0.05 level (Table 2, Figure 5 ). Although none of these 11 SNPs were the exact SNPs that were significantly associated with asparaginase IC 50 in CEU cell lines, two genes in this pathway, argininosuccinate synthetase 1 (ASS1) and asparaginyl-tRNA synthetase 2 (NARS2), had polymorphisms that were associated with asparaginase sensitivity in both ALL patient samples and CEU cell lines (Supplementary Table S2 ). The highest-ranked SNP (rs3102475) in patient samples was in the adenylosuccinate synthetase (ADSS) gene.
Discussion
We used an agnostic genome-wide approach to identify inherited genomic variants that may contribute to interindividual variation in asparaginase sensitivity. Of all annotated biological pathways, the aspartate metabolism pathway was the most overrepresented among the 94 genes hosting the SNPs associated with asparaginase sensitivity. Remarkably, aspartate homeostasis lies at the heart of the putative mechanism of action of asparaginase.
Our genome-wide approach has identified genotypes of SNPs in the aspartate metabolism pathway that contribute significantly to asparaginase sensitivity, including polymorphisms in ADSL, DARS, ASS1, aspartyl-tRNA synthetase 2 (DARS2), NARS2, and adenylosuccinate synthetase like1 (ADDSSL1). Two of these genes, ASS1 and NARS2, harbored additional SNPs that were associated with asparaginase sensitivity in primary ALL samples, and several of these gene products have been reported by others to be directly related to asparaginase resistance in leukemic cells. 17 The urea cycle enzyme, ASS1, is involved in the synthesis of arginine, 36 and increased arginine synthesis may help promote the propagation of leukemic cells. 37 Upregulation of ASS1 conferred resistance in leukemic cells, whereas suppression of ASS1 by RNA interference restored asparaginase sensitivity. 17 ALL cells have a relatively high rate of de novo purine synthesis, 38, 39 and several enzymes involved in the purine metabolism pathway are important targets for antimetabolites (for example, mercaptopurine and methotrexate) that are the cornerstone of continuation therapy for childhood ALL. 40 The biosynthesis of adenosine monophosphate from inosine monophosphate involves two steps, the first step involving catalysis by ADSS and the second by ADSL. In a recent genome-wide analysis of genes, the expression of which differed at relapse compared with that at diagnosis of ALL, ADSL was overexpressed in samples obtained at relapse compared with samples obtained at diagnosis from the same individual. 41 Moreover, ADSL expression was marginally higher at diagnosis in patients who subsequently relapsed. 42 Consistent with these findings, our data showed that ADSL expression was related to asparaginase resistance, and that two common germline polymorphisms in this gene might be the basis for both increased ADSL expression and increased resistance (Supplementary Figure S3) . ADSL has been reported to be elevated in some malignancies such as colorectal, breast and prostate cancer, and in gliomas. [43] [44] [45] DARS, DARS2 and NARS2 form part of a clinically important family of cytoplasmic enzymes that have a crucial role in protein synthesis. Our previous findings have shown that asparaginase-resistant and -sensitive leukemic cells differ significantly in the expression levels of genes involved in protein synthesis. 24 It is possible that an altered intracellular amino acid metabolism, particularly that involving aspartate or asparagine, might rescue cells from the effects of asparaginase.
The presence of primary or acquired elevated levels of ASNS has been considered as a main cause of asparaginase Allele with higher IC 50 in primary ALL samples.
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resistance. [11] [12] [13] [14] However, data from some recent studies (Supplementary Table S7 ) on the importance of ASNS are conflicting. [17] [18] [19] [20] [21] [22] [23] 26, 46 Here, we found no associations between germline polymorphisms in ASNS and asparaginase resistance.
Ex vivo sensitivity of ALL blasts to asparaginase has also been associated with ALL subtypes, [47] [48] [49] with sensitive subtypes tending to be those with better event-free survival rates. The fact that we did not demonstrate that asparaginase sensitivity differed significantly among subtypes likely relates to the relatively small number of samples in each subtype. Ex vivo sensitivity to asparaginase has been associated with in vivo clinical response to asparaginase after up-front window exposures, 9 as well as for long-term event-free survival, [5] [6] [7] [8] and thus ex vivo drug sensitivity may be an important phenotypic characteristic of primary ALL cells.
We focused on inherited genomic variations in DNA as possible determinants of asparaginase sensitivity, whereas previous studies 18, 24 focused on variation in gene expression levels. One reason for focusing on germline genomic variation is that predictive testing is more likely to be useful using germline DNA than using gene expression, which varies among tissue types and over time. Moreover, genomic variation can be associated with phenotypes such as drug sensitivity and not be reflected in differences in gene expression. [50] [51] [52] Nevertheless, we did observe that two SNPs in ADSL that were associated with higher IC 50 were also associated with higher ADSL expression, and high ADSL expression was associated with higher IC 50 .
We acknowledge that in vitro tests of drug sensitivity in lymphoblastoid cell lines will not be perfect models for in vivo sensitivity of leukemic cells, nor of other host toxicities to asparaginase, such as pancreatitis or thrombosis. 53 Nevertheless, these HapMap cell lines have been used to identify genomic variation associated with susceptibility to other anticancer agents, and that variation has been shown to be highly heritable. 35, 54 The lack of overlap in SNPs associated with drug sensitivity in CEU compared with YRI cell lines can be partially explained by a difference in allele frequency and by different penetrance of SNPs in the two distinct populations. 54 Moreover, Figure 5 The distribution of asparaginase IC 50 vs genotypes for 11 SNPs annotated to genes in the aspartate metabolism pathway at the Po0.05 level in ALL patient samples. Boxes include data between the 25th and 75th percentiles, and whiskers indicate the minimal and maximal values excluding outliers.
although it is possible that some germline variation that affects anticancer drug sensitivity may be related to nonspecific mechanisms that apply to all proapoptotic stimuli, we found a relatively modest overlap (Supplementary Table S4 ) among SNP genotypes associated with sensitivity to asparaginase vs to other unrelated antileukemic agents, suggesting that the majority of the top-ranked SNPs were asparaginase specific. In addition, we and others have shown some genotype/phenotype associations in lymphoblastoid cell lines that replicate those that have been observed clinically, as well as in other primary tissue types. [54] [55] [56] In this work, we showed an overlap in that the primary pathway (aspartate metabolism) associated with sensitivity in the HapMap cell lines was also associated in primary ALL cells. Therefore, HapMap resources are a useful adjunctive tool for pharmacogenetic discovery.
In the present study, there was evidence for validation that the top ranked pathway (that is, the aspartate metabolism pathway) in CEU cell lines was also relevant in ALL samples. Given the high degree of heterogeneity among ALL subtypes, and the somatically acquired genomic variants that distinguish ALL subtypes from each other and from normal cells, it is not surprising that some determinants of asparaginase sensitivity in ALL are likely due to genomic factors other than inherited genomic variation, consistent with previous findings that genomic determinants of drug effects differ in cell lines and primary ALL samples. 18, 57 In summary, our genome-wide interrogation of HapMap cell lines and primary ALL blasts has revealed that inherited genomic variation in a plausible candidate pathway (aspartate metabolism) contributes to interindividual variation in asparaginase sensitivity in both normal cells and in primary ALL cells.
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